RELATLIMAB for Chordoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 8 adverse event reports in the FDA FAERS database where RELATLIMAB was used for Chordoma.
Most Reported Side Effects for RELATLIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Pneumonia | 13 | 7.3% | 7 | 9 |
| Malignant neoplasm progression | 9 | 5.1% | 7 | 7 |
| Myocarditis | 8 | 4.5% | 1 | 6 |
| Hypotension | 7 | 4.0% | 0 | 7 |
| Meningitis aseptic | 7 | 4.0% | 0 | 7 |
| Pyrexia | 7 | 4.0% | 0 | 6 |
| Sepsis | 7 | 4.0% | 4 | 5 |
| Adrenal insufficiency | 6 | 3.4% | 0 | 6 |
| Drug ineffective | 6 | 3.4% | 0 | 2 |
| Hepatitis | 6 | 3.4% | 1 | 5 |
| Myositis | 6 | 3.4% | 1 | 5 |
| Pericardial effusion | 6 | 3.4% | 0 | 6 |
| Dyspnoea | 5 | 2.8% | 1 | 5 |
| Headache | 5 | 2.8% | 0 | 3 |
| Hyponatraemia | 5 | 2.8% | 0 | 5 |
Other Indications for RELATLIMAB
Malignant melanoma (69)
Non-small cell lung cancer (26)
Acute myeloid leukaemia (11)
Glioblastoma multiforme (8)
Head and neck cancer (6)
Metastatic malignant melanoma (6)
Other Drugs Used for Chordoma
IMATINIB (85)
NIVOLUMAB (24)
CARBOPLATIN (16)
ETOPOSIDE (13)
EVEROLIMUS (13)
IFOSFAMIDE (10)
PALBOCICLIB (10)
TOPOTECAN (10)
PAZOPANIB (9)
IPILIMUMAB (8)